Aptar Pharma introduces new respiratory drug delivery device

4 October 2018 (Last Updated November 22nd, 2018 11:20)

Drug delivery systems provider Aptar Pharma has introduced a new portable, drug delivery device called PureHale to help relieve the symptoms of upper respiratory system disorders.

Aptar Pharma introduces new respiratory drug delivery device
PureHale with mask option. Credit: AptarGroup, Inc.

Drug delivery systems provider Aptar Pharma has introduced a new portable, drug delivery device called PureHale to help relieve the symptoms of upper respiratory system disorders.

The new ready-to-use solution can be used to deliver natural ingredient formulations such as saline.

Using the company’s Bag-on-Valve technology, PureHale is designed to generate a continuous fine mist of 20-30µm that will cleanse, moisturise and soothe the upper respiratory tract.

“The new drug delivery device enables on-the-go use because it does not require batteries or external charging, unlike conventional nebulisers.”

The drug delivery device will aid in decreasing irritations caused due to coughs, colds, allergies, respiratory problems and dry nose/throat conditions.

Aptar Pharma Consumer Healthcare division president Thomas Klofac said: “PureHale enables pharmaceutical partners to expand their audience reach for their brand formulations, providing portable, symptomatic relief for upper respiratory system conditions.”

The company added that the new drug delivery device enables on-the-go use because it does not require batteries or external charging, unlike conventional nebulisers.

PureHale is light and available with different mask and mouthpiece options for adaptable treatment.

Aptar Pharma Business Development director Guenter Nadler said: “We have seen a real need for a device of this kind – traditional nebulisers come with a set of challenges including complexities in setup, manual dexterity requirements and overall usage time.

“Meanwhile, challenges during medication administration include poor inhalation technique, duration of nebulisation and understanding how to achieve optimal efficacy. PureHale has been designed specifically with these challenges in mind and offers a solution by simplifying the entire process.”

The company will officially launch PureHale on 9 October 2018 at CPhI Worldwide in Madrid, Spain.